Patents Assigned to Transmedi SA
  • Patent number: 9068988
    Abstract: The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells hearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 30, 2015
    Assignee: TRANSMEDI SA
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard
  • Patent number: 8288091
    Abstract: The present invention relates to the identification of a novel mechanism of transcription infidelity in cells. The invention provides compositions and methods to detect the level of transcript ion infidelity in a sample, as well as the use thereof, e.g., for therapeutic, diagnostic, pharmacogenomic or drug design. As will be disclosed, the invention is particularly suited for detecting, monitoring or treating proliferative cell disorders, for the design and/or screening of drugs, for patient or disease profiling, prediction of disease severity and evaluation of drug efficacy.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: October 16, 2012
    Assignee: Transmedi SA
    Inventor: Bernard Bihain
  • Publication number: 20110097743
    Abstract: The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by measuring the levels of antibodies against particular aberrant protein domains in a sample from the subject, or the presence or number of immune cells bearing TCR specific for such aberrant protein domains. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects.
    Type: Application
    Filed: December 15, 2008
    Publication date: April 28, 2011
    Applicant: TRANSMEDI SA
    Inventors: Bernard Bihain, Virginie Ogier, Marie Brulliard
  • Publication number: 20090317386
    Abstract: The present invention relates to the identification of a novel mechanism of transcription infidelity in cells. The invention provides compositions and methods to detect the level of transcript ion infidelity in a sample, as well as the use thereof, e.g., for therapeutic, diagnostic, pharmacogenomic or drug design. As will be disclosed, the invention is particularly suited for detecting, monitoring or treating proliferative cell disorders, for the design and/or screening of drugs, for patient or disease profiling, prediction of disease severity and evaluation of drug efficacy.
    Type: Application
    Filed: July 20, 2007
    Publication date: December 24, 2009
    Applicant: TRANSMEDI SA
    Inventor: Bernard Bihain